Clinical trials
Primary Breast Cancer clinical trials
Below are recruiting primary breast cancer clinical trials, each written for real people, not researchers. We’re tracking 715 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06525766RecruitingPhase 2
Adaptive capecitabine therapy for metastatic ER+ HER2− breast cancer
This trial tests whether adjusting the dose of the oral chemotherapy capecitabine over time can control metastatic breast cancer that is estrogen-receptor positive (ER+) and HER2−. It is designed for patients who are starting capecitabine or have just started it, and the study will monitor blood changes and tumor response closely.
Scottsdale, ArizonaAges 18 years+ - NCT07502820RecruitingPhase 3
Personalized tamoxifen dosing for breast cancer
This trial tests whether adjusting the dose of tamoxifen based on your body's processing can improve treatment for hormone-sensitive breast cancer. It aims to find the best dose for you while keeping side effects manageable.
BoråsAges 18 years+ - NCT06263543RecruitingPhase 2
Sequencing antibody-drug conjugates in ER+, HER2-low breast cancer
This trial tests different sequences of antibody-drug conjugates (a type of targeted chemotherapy) for people with ER-positive, HER2-low or ultra-low metastatic breast cancer that has stopped responding to hormone therapy and has progressed on Enhertu. You must have had 1–4 prior chemotherapies for metastatic disease.
Miami, FloridaAges 18 years+ - NCT05072314RecruitingPhase 3
Lidocaine drip after breast surgery to improve long-term pain
This Phase 3 study tests whether a long-running lidocaine (a numbing medicine) drip given around the time of breast surgery can improve long-term post-surgery pain and recovery. It may help people who have pain after mastectomy or breast-conserving surgery.
Kingswood, New South WalesAges 18 years+ - NCT07752238Recruiting
Predicting outcomes for newly diagnosed metastatic breast cancer
This study uses information from women with newly diagnosed breast cancer that has spread (metastatic) to create a tool that helps predict how the disease may progress. By looking at your medical records, they hope to improve care and help future patients.
Szombathely, Vas CountyAges 18 years+ - NCT05327608RecruitingPhase 2
Time-restricted eating during breast cancer chemotherapy
This study is testing whether time-restricted eating (confining all meals to a specific window each day) can improve the response to chemotherapy in women with newly diagnosed breast cancer. Participants will follow this eating pattern for 16 weeks while receiving their standard chemotherapy, and the researchers will monitor how the tumor shrinks.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04517266Recruiting
Testing less radiation to the inner breast area
This trial studies whether some patients with early-stage breast cancer can safely skip a specific part of radiation to the inner chest (called internal mammary irradiation). It may reduce radiation side effects while still aiming to prevent the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07391774RecruitingPhase 3
Hormone therapy with or without chemo for early breast cancer
This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.
Jonesboro, ArkansasAges 18 years+ - NCT07304934Recruiting
New blood test model to check lymph node status in breast cancer
This study uses a blood test and imaging to predict whether breast cancer has spread to underarm lymph nodes, helping guide surgery. It may reduce unnecessary lymph node removal.
Hangzhou, ZhejiangAges 18 years+ - NCT06058377RecruitingPhase 3
Adding immunotherapy to chemo for stage II-III breast cancer
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy works better than chemo alone for people with hormone receptor positive, HER2 negative breast cancer that is stage II or III and has a high-risk genetic score (MammaPrint High Risk 2).
Birmingham, AlabamaAges 18 years+ - NCT05512364RecruitingPhase 3
Elacestrant for ER-positive, HER2-negative breast cancer with ctDNA relapse
This trial tests whether elacestrant can help stop or delay breast cancer coming back in people whose blood test shows “ctDNA relapse” after early breast cancer treatment. It’s meant for hormone receptor–positive, HER2-negative breast cancer patients who are already taking hormone (endocrine) therapy and have no visible spread on scans.
AnderlechtAges 18 years+ - NCT06781281Recruiting
Chemo plus immunotherapy for early HR+/HER2- breast cancer
This trial tests adding an immunotherapy drug (serplulimab) to standard chemotherapy for early-stage HR+/HER2- breast cancer. The goal is to see if the combination works better than chemo alone before surgery.
ZhengzhouAges 18 years+ - NCT06217185RecruitingPhase 4
Pyrotinib and trastuzumab with chemo for HER2+ advanced breast cancer
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
Shijiazhuang, HebeiAges 18–70 - NCT06042569RecruitingPhase 2
Lower-dose chemo for older women with HER2-negative breast cancer
This trial tests whether a lower dose of two chemotherapy drugs (docetaxel and cyclophosphamide) works well for women 65 and older with early-stage HER2-negative breast cancer. The goal is to maintain effectiveness while reducing side effects in this group.
Duarte, CaliforniaAges 65 years+ - NCT05642897Recruiting
Mind program for women receiving breast cancer radiotherapy
This trial tests a “Mind Programme” designed to support women with breast cancer who are currently receiving radiation treatment. It may help with emotional well-being during radiotherapy, but you must meet specific health and language requirements.
CoimbraAges 18–70 - NCT05464810RecruitingEarly Phase 1
Letrozole with or without a cholesterol drug for early breast cancer
This early-phase study tests whether adding simvastatin to letrozole can improve outcomes in people with stage I–III breast cancer that grows with hormone signals (hormone receptor positive) and does not have HER2. It looks mainly at whether the approach is safe and useful for this specific breast cancer type.
Atlanta, GeorgiaAges 18 years+ - NCT04985266RecruitingPhase 2
Watch blood DNA for early breast cancer return, then add palbociclib
This study checks for early signs that ER-positive, HER2-negative breast cancer may be coming back by testing your blood for cancer DNA. If signs are found, it tests whether adding palbociclib plus fulvestrant works better than standard hormone therapy alone to prevent recurrence.
AngersAges 18 years+ - NCT04517838Recruiting
Testing immune responses to anti-HER2 breast cancer treatments
This study looks at how your immune system reacts to anti-HER2 treatments in people with HER2-positive breast cancer. It may help doctors understand who responds best by studying immune signals in blood (and sometimes tissue) during or after treatment.
Jacksonville, FloridaAges 18 years+ - NCT06179303RecruitingPhase 2
Imaging to predict response to abemaciclib for advanced breast cancer
This trial tests if a special PET scan can predict how well the drug abemaciclib works for people with advanced hormone receptor-positive, HER2-negative breast cancer. If you qualify, you would receive abemaciclib and have imaging scans to see if your cancer responds.
St Louis, MissouriAges 18 years+ - NCT06723990Recruiting
HER2 breast cancer treatment decision study
This study tests a tool called HER2DX to help doctors choose the best treatment for early stage HER2 positive breast cancer. It may help tailor therapy before or after surgery.
Milan, ItalyAges 18 years+ - NCT06762977Recruiting
Study on her2-positive early-stage breast cancer treatment
This study looks at how well a new test can help manage her2-positive early-stage breast cancer. It includes patients who have had treatment before or after surgery with trastuzumab and possibly pertuzumab.
BrindisiAges 18 years+ - NCT05467891RecruitingPhase 2
Ribociclib plus hormone therapy for recurrent breast cancer
This trial tests whether adding ribociclib (a targeted pill) to hormone therapy can control breast cancer that has come back in the breast area or nearby lymph nodes/chest wall. It targets hormone-receptor–positive and HER2-negative tumors to help slow disease after local treatment.
Birmingham, AlabamaAges 18 years+ - NCT04547907RecruitingPhase 3
Testing two HER2 breast cancer medicines before surgery
This trial compares two anti-HER2 medicines given before surgery to shrink HER2-positive early breast cancer. It aims to see which treatment works better as “neoadjuvant” therapy to improve outcomes while keeping you safe.
Zhengzhou, HenanAges 18–70 - NCT06595563RecruitingPhase 2
PET imaging to guide HER2 breast cancer treatment sequencing
This study tests whether a special PET scan using a radioactive tracer can help doctors choose the right sequence of antibody-drug conjugates for HER2-positive advanced breast cancer. It is for patients whose cancer has already progressed on the drug T-DXd (Enhertu).
Anderlecht, Brussels CapitalAges 18 years+
Hear when a new Primary Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for primary breast cancer?
- Yes. Clin2 currently lists 715 recruiting primary breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.